Anti-PML (Human) mAb
Anti-PML (Human) mAb Specifications
|Background:||Acute promyelocytic leukemia (APL) is associated with a t(15;17) translocation that creates the promyelocyte-retinoic acid receptor ï¡ (PML-RARï¡) fusion protein and successfully differentiated by all-trans-retinoic acid (ATRA). PML-RARï¡ consists of all amino acid of RARï¡ except the first 59 amino acids and includes its DNA-binding and ligand-binding domains. PML-RARï¡ contains the functional domains of PML which includes the DNA binding and dimerization property. Thus, the functions of PML and/or retinoid X receptor are sequestrated by PML-RARï¡ in a dominant negative manner. In APL cells, the PML-RARï¡ and PML are immunologically localized as microgranules in the nuclei and cytoplasm, whereas in normal cells, PML is immunologically found as a discrete speckled pattern in nuclei. The ATRA treatment of the APL cells triggers a reorganization of PML to generate normal localization. Anti-PML antibody is a strong tool for the detection of the chromosomal translocation t(15;17) on the APL cells and/or determination of the sensitivity of the APL cells to the ATRA differentiation of hematopoietic cells and apoptosis.
|Formulation:||1 mg/mL in PBS/50% glycerol, pH 7.2|
|Gene ID Human:||5371|
|Gene ID Mouse:||18854|
|Immunogen:||Recombinant Human fulll length PML|
|Regulatory Statement:||For Research Use Only. Not for use in diagnostic procedures.|
|Product Type:||Primary Antibody|
Applications: FCM, IC, IP, WB
|IPP:||Optimal Dilution to be determined by end user.|
There are no references for Anti-PML (Human) mAb at this time.